ADC
Showing 1 - 25 of 1,252
Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)
Not yet recruiting
- Gastric Cancer
- RC48-ADC
- +4 more
-
Beijing, ChinaBeijing Cancer Hospital
Aug 7, 2023
RC48-ADC in Breast Cancer
Not yet recruiting
- Breast Cancer
- Disitamab vedotin
- (no location specified)
Apr 30, 2023
Non-muscle Invasive Bladder Cancer Trial in Chengdu (RC48-ADC)
Not yet recruiting
- Non-muscle Invasive Bladder Cancer
-
Chengdu, Sichuan, ChinaWest China Hospital
Aug 10, 2023
Advanced Breast Cancer Trial (Disitamab vedotin)
Not yet recruiting
- Advanced Breast Cancer
- Disitamab vedotin
- (no location specified)
Apr 16, 2023
NMIBC Trial in Beijing (RC48-ADC in Combination with gemcitabine)
Recruiting
- NMIBC
- RC48-ADC in Combination with gemcitabine
-
Beijing, Beijing, ChinaPeking University First Hosptital
Jul 10, 2023
Metastatic Castration-resistant Prostate Cancer Trial (Disitamab Vedotin(RC48-ADC))
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- Disitamab Vedotin(RC48-ADC)
- (no location specified)
Jul 13, 2023
Carcinoma, Upper Tract Urothelial Carcinoma, UTUC Trial in Nanjing (RC48-ADC and JS001)
Recruiting
- Carcinoma
- +2 more
- RC48-ADC and JS001
-
Nanjing, Jiangsu, ChinaJinling Hospital, Affiliated Hospital of Medical School, Nanjing
Jun 15, 2023
Colorectal Cancer Trial in Hangzhou (RC48-ADC plus Bevacizumab)
Not yet recruiting
- Colorectal Cancer
- RC48-ADC plus Bevacizumab
-
Hangzhou, Zhejinag, ChinaThe second affiliated hospital of Zhejiang University
Mar 24, 2023
Solid Tumor Trial (Disitamab vedotin)
Not yet recruiting
- Solid Tumor
- Disitamab vedotin
- (no location specified)
Jul 10, 2023
Cervical Cancer Trial in China (Disitamab Vedotin, Zimberelimab)
Not yet recruiting
- Cervical Cancer
- Disitamab Vedotin
- Zimberelimab
-
Bengbu, Anhui, China
- +11 more
Nov 23, 2023
HER2-positive Advanced Breast Cancer Patients Treated With ADC
Recruiting
- Breast Cancer
- HER2 expression of circulating tumor cells
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Apr 18, 2023
HER2-low Advanced Breast Cancer Patients Treated With ADC
Recruiting
- Breast Cancer
- HER2 expression of circulating tumor cells
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Apr 18, 2023
Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)
Not yet recruiting
- Triple-negative Breast Cancer
- A1: SHR-A1811
- +11 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 19, 2023
HIV Vaccine Trial in São Paulo (Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides, Alpha-type-1
Not yet recruiting
- HIV Vaccine
- Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
- +2 more
-
São Paulo, BrazilHospital das Clínicas da Faculdade de Medicina da USP
Mar 14, 2023
Solid Tumor Trial in United States (TR1801-ADC)
Active, not recruiting
- Unspecified Adult Solid Tumor, Protocol Specific
- TR1801-ADC
-
Los Angeles, California
- +4 more
Oct 30, 2022
Chronic Hepatitis B Trial in Hong Kong, Auckland (VRON-0200-AdC6, VRON-0200-AdC7)
Recruiting
- Chronic Hepatitis B
- VRON-0200-AdC6
- VRON-0200-AdC7
-
Hong Kong, Hong Kong
- +1 more
Oct 6, 2023
Salivary Gland Tumors Trial in Beijing (RC48-ADC)
Recruiting
- Salivary Gland Tumors
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 28, 2022
Chronic Lymphocytic Leukemia Trial (Loncastuximab Tesirine)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Loncastuximab Tesirine
- (no location specified)
Jul 24, 2023